TNF-α mediated upregulation of Na\textsubscript{V}1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation

Flávio Henrique Pequeno de Macedo\textsuperscript{1}, Rosária Dias Aires\textsuperscript{1}, Esdras Guedes Fonseca\textsuperscript{1}, Renata Cristina Mendes Ferreira\textsuperscript{1}, Daniel Portela Dias Machado\textsuperscript{1}, Lina Chen\textsuperscript{2}, Fang-Xiong Zhang\textsuperscript{2}, Ivana A. Souza\textsuperscript{2}, Virginia Soares Lemos\textsuperscript{1}, Thiago Roberto Lima Romero\textsuperscript{1}, Aubin Moutal\textsuperscript{3}, Rajesh Khanna\textsuperscript{3}, Gerald W. Zamponi\textsuperscript{2*} and Jader S. Cruz\textsuperscript{1*}

Abstract
Clinical and preclinical studies have shown that patients with Diabetic Neuropathic Pain (DNP) present with increased tumor necrosis factor alpha (TNF-α) serum concentration, whereas studies with diabetic animals have shown that TNF-α induces an increase in Na\textsubscript{V}1.7 sodium channel expression. This is expected to result in sensitization of nociceptor neuron terminals, and therefore the development of DNP. For further study of this mechanism, dissociated dorsal root ganglion (DRG) neurons were exposed to TNF-α for 6 h, at a concentration equivalent to that measured in STZ-induced diabetic rats that developed hyperalgesia. Tetrodotoxin sensitive (TTXs), resistant (TTXr) and total sodium current was studied in these DRG neurons. Total sodium current was also studied in DRG neurons expressing the collapsin response mediator protein 2 (CRMP2) SUMO-incompetent mutant protein (CRMP2-K374A), which causes a significant reduction in Na\textsubscript{V}1.7 membrane cell expression levels. Our results show that TNF-α exposure increased the density of the total, TTXs and TTXr sodium current in DRG neurons. Furthermore, TNF-α shifted the steady state activation and inactivation curves of the total and TTXr sodium current. DRG neurons expressing the CRMP2-K374A mutant also exhibited total sodium current increases after exposure to TNF-α, indicating that these effects were independent of SUMOylation of CRMP2. In conclusion, TNF-α sensitzes DRG neurons via augmentation of whole cell sodium current. This may underlie the pronociceptive effects of TNF-α and suggests a molecular mechanism responsible for pain hypersensitivity in diabetic neuropathy patients.

Keywords: Diabetic neuropathic pain, Tumor necrosis factor, DRG neurons, Sodium channel Na\textsubscript{V}1.7

Introduction
The World Health Organization (WHO) defines diabetes as a chronic disease that results from poor insulin production or the inability of the body to use it efficiently. As a result, basal glucose concentration in the bloodstream rises, resulting in hyperglycemia [1]. According to estimates, 9% of the world’s population over 18 years old are affected by diabetes [2], while around 1.6 million deaths were caused directly by diabetes, in 2016 [3]. The WHO projection points out that, by 2030, diabetes will be the 7th major cause of death in the world [4]. Patients with diabetes suffer from macrovascular complications, such as myocardial infarction, stroke, peripheral vascular disease, microvascular complications that manifest as peripheral neuropathy, retinopathy and nephropathy [5]. Diabetes is the main cause of peripheral neuropathy [6]. Among the various types of diabetic neuropathy, the most common clinical manifestation is distal symmetric polyneuropathy, also called peripheral diabetic neuropathy (PDN), which affects 75% of patients with diabetic neuropathy [7]. Approximately 20 to 30% of patients with PDN suffer from diabetic neuropathic pain (DPN), one of the main clinical consequences of PDN [8, 9].
Studies in Streptozocin (STZ)-induced diabetic rats show that the development of hyperalgesia presented by these animals is associated with an increased expression of voltage-dependent sodium (NaV) channels [10, 11]. In addition, patch clamp recordings indicated increased TTX-sensitive sodium current density consistent with increased expression of the NaV1.3, 1.6 and 1.7 isoforms [12–14]. Among these, the NaV1.7 isoform has been directly linked to diabetic neuropathy and the release of proinflammatory cytokines [11, 15–17]. These channels are mostly expressed in small diameter Aδ and C fibers [18] and, not surprisingly, in 85% of functionally identified nociceptors [19]. In addition, NaV1.7 expression is increased in DRG neurons of STZ-induced diabetic rats, a change that contributes to pain-related hypersensitivity [11, 16, 20]. In PDN, increased tumor necrosis factor α (TNF-α) expression in dorsal root ganglion (DRG) neurons was linked to increased NaV 1.7 levels and nociceptive behaviors.

Here, we first determined the TNF-α serum concentration in a rat model of PDN and then assessed, for the first time, the effects of this specific and physiologically relevant concentration on whole cell sodium currents in DRG neurons from normoglycemic rats. Then, we investigated whether manipulating a recently reported NaV1.7 trafficking regulator, the collapsin response mediator protein 2 (CRMP2) [21], could normalize the TNF-α mediated increase in NaV1.7 function. CRMP2 is a cytosolic phosphoprotein that is dysregulated in neuropathic pain [8, 22]. Its function as a trafficking regulator for NaV1.7 [21, 23, 24] was suggested to be instrumental in regulating allodynic and hyperalgesic behaviors in various rodent models of pain [5, 6]. When SUMOylated, CRMP2 protects NaV1.7 from endocytosis thus maintaining the availability of the channel for voltage-dependent activation and nociceptive transmission [22, 23]. Inhibition of CRMP2 SUMOylation efficiently decreased NaV1.7 surface localization and currents [25]. Thus, we hypothesized that inhibiting CRMP2 SUMOylation might reverse the increased NaV1.7 currents induced by TNF-α. However, as we show here, although TNF-α increases sodium current density, these effects occur independently of CRMP2 SUMOylation.

Materials and methods
Experiments were approved by the Institutional Animal Care and Use Committee from the Federal University of Minas Gerais (protocol number 233/2013) and by the Health Sciences Animal Care Committee, from the University of Calgary (protocol number AC13–0045).

Induction of experimental diabetes
28 day old male Wistar rats were randomly assigned to both the diabetic and control groups. Rats in the diabetic group were fasted overnight before receiving a single intraperitoneal injection of STZ solution (65 mg/kg diluted in a 10 mM sodium citrate buffer solution, pH of 4.5) [26]. Rats in the control group received only sodium citrate buffer solution. As shown by Junod et al. [27], this single STZ dose induces a severe hypoglycemic state within 7 hours, and this matches the time course of development of hyperinsulinemia. Following STZ injection, waterers containing a 10% glucose solution were placed in the rat cages to reduce or prevent hyperinsulinemia and hypoglycemic shock [28]. Glycemia levels were assessed using blood samples (Accu-Check Active®, Roche) obtained immediately before STZ injection (day 0), and then monitored fortnightly until the day 60 after diabetes induction. Animals with blood glucose levels over 300 mg/dl were considered diabetic.

Evaluation of mechanical hyperalgesia
Mechanical hyperalgesia was assessed by the use of a Randall–Selitto device (Ugo-basile, 37,215, Verase, Italy), through which an increasing pressure (32 g/s) was applied to the dorsal portion of the rats’ back paws. The force (g) that led the rat to withdraw its paw was considered as the mechanical nociceptive threshold. The increasing pressure cutoff was set at 250 g to prevent tissue damage [22].

Quantification of TNF-α by ELISA
At the day before and at day 60 after STZ injection, 0.5 to 1.5 ml of blood samples were collected from the rats’ arterial tails by using a peripheral intravascular catheter (24G needle) perfused with sodium citrate (1 mM) to avoid coagulation during blood collection. Samples were kept at room temperature for 10 min, followed by refrigeration (4 °C) for 10 min to form the clot to obtain serum blood. The samples were then centrifuged (1300 RPM, 5 min) and the supernatant was collected. Plasma concentration of TNF-α was quantified with rat-specific ELISA kits (Duoset kits; R&D Systems) using the Thermoscientific Multiskan FC. Kits were used in accordance with manufacturer’s instructions.

DRG neuron dissociation
Sprague-Dawley rats (5–6 weeks old) were anesthetized with isoflurane and decapitated by the use of guillotine. After access to the spinal cord, 40–50 DRGs were aseptically dissected from cervical, thoracic and lumbar spinal segments, and kept in ice-cold PBS (in mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4 and 2 KH2PO4). After cleaning, DRGs were subjected to enzymatic digestion. To that end, they were exposed to 1 ml of F12 culture medium solution (supplemented with 10% v/v fetal bovine serum and 1% v/v penicillin-streptomycin solution) with the addition of 40 µl of papain and 4 mg of collagenase type 1 for 30 min (Invitrogen), kept in a water bath at 37 °C. The DRGs were slightly shaken every 5 min. Then the medium was replaced for the addition of 0.4% type IV
DNAse (Sigma). The DRGs were kept for another 10 min in the water bath. After digestion, the culture medium was replaced 3 times in order to eliminate the digestive enzymes. DRGs were cautiously thinned by the use of a 1000 μl auto-pipette and the neurons were transferred to a supplemented F12 culture medium (B27 (2%), L-glutamine (1%), N2 (1%) and NGF (0.1%), Gibco). The dissociated DRG neurons were then distributed into a 24-well plate containing coverslips pretreated with laminin (1%) and Poly-D-lysine (10%). 600 μl of medium containing cells was added to each well. The 24-well plate was kept in the incubator (5% CO2–95% O2, 37 °C) until the cells were used. For the study of the TNF-α effect on the total sodium current in transfected DRG neurons, the cells were kept in culture for a period of 2 weeks. For the study of the effect of TNF-α on the TTXs and TTXr sodium currents, cells were used after a minimum time period of 12 h in culture.

**Virus production for infection of dissociated DRG neurons**

For the infection of the dissociated DRG neurons, the AAV5 recombinant adenovirus (AAV5 Helper-Free System, Agilent Technologies Stratagene Products Division, CA, USA) kit was used. The kit contains three vectors: pAAV-MSC, pAAV-RC5 and pHelper. The first vector contained the genes of interest, CRMP2-WT and CRMP2-K374A, both tagged with GFP (Green Fluorescent Protein). These constructs were transfected into immortalized cells of the 293AAV line (by the use of calcium phosphate buffer solution) concomitantly with the vectors pAAV-RC5 and pHelper, a process that results in the production of viruses specific for infection of DRG neurons and containing the constructs of interest, CRMP2-WT-GFP and CRMP2-K374A-GFP, as viral materials. 24–72 h post-transfection, the viruses were extracted from the 293AAV cells accordingly with the instructions of a virus purification kit (Takara AAVpro® Purification Kit, TAKARA BIO INC), resulting in solutions containing 5·10⁷ virus Gc/μl (genomic copies per microliter).

**DRG neuron infection**

12–18 h after dissociation of the DRG neurons, 5 μl of solution containing the GFP-CRMP2-WT virus or 10 μl of solution containing the GFP-CRMP2-K374A virus was added to each well. Viruses were maintained in the culture for 72 h, after which the medium was replaced for a B27 (2%), L-glutamine (1%), N2 (1%) and NGF supplemented F12 medium. After 2 weeks in culture, successfully infected neurons emitted GFP fluorescence (Zeiss LSM-510, λ = 488 nm), confirming that they expressed the plasmid.

For the study of the TNF-α exposure effect on the total Na⁺ current in infected cells, TNF-α (TNF Recombinant Rat Protein, Thermo Fisher Scientific) was added to the culture medium at a concentration of 700 pg/ml for 6 h, after which the cells had measured their total Na⁺ current in a Patch Clamp platform.

---

Fig. 1 Glucose level and behavioral analysis in diabetic rats. a Glycemia values measured biweekly. n represents the number of rats * p < 0.05 control vs diabetic; Two Way ANOVA test followed by Bonferroni. b Mechanical thresholds measured biweekly. * p < 0.05 control vs diabetic. Two Way ANOVA test followed by Bonferroni. c TNF serum concentration dosage in the Control and Diabetic group for both day 0 and 60. n reflects numbers of rats. * p < 0.05 control vs diabetic; One Way ANOVA test followed by Bonferroni.
Electrophysiology

The total Na⁺ current was recorded by using the amplifier Axoclamp 200B in the whole cell voltage clamp configuration in combination with the Clampex 9.2 software (Molecular Devices, Sunnyvale, CA). Low resistance patch electrodes (3–4 MΩ) were filled with solution containing (in mM): 10 NaCl, 100 CsCl, 5 MgCl₂, 10 HEPES and 11 EGTA and 10 TEA-Cl, pH 7.2 adjusted with 1 M CsOH. 10 NaCl, 100 CsCl, 5 MgCl₂, 10 HEPES and 11 EGTA and 10 TEA-Cl, pH 7.2 adjusted with 1 M CsOH. Cells were initially kept in a bath solution containing (in mM): 50 NaCl, 5 CsCl, 0.1 CdCl₂, 0.5 MgCl₂, 60 Glucose and 5 HEPES, pH 7.4 adjusted with 1 M NaOH. After reaching the whole cell configuration, the cell was perfused with external solution containing (in mM): 40 NaCl, 3 KCl, 1 CaCl₂, 1 MgCl₂, 0.1 CdCl₂, 20 TEA-Cl, 70 Choline-Cl, 10 HEPES and 10 Glucose, pH 7.4 adjusted with 1 M HCl/NaOH. Liquid junction potentials between internal and bath solutions (−0.5 mV) and between internal and external solutions (4.8 mV) were corrected before any recordings. An Ag-AgCl electrode was used as reference. The recordings were filtered with a Bessel lowpass filter set at 2.9 kHz and digitalized at a 20 kHz (50 μs interval) through a Digidata 1320A interface board. Capacitive currents were electronically compensated and a P/4 protocol was used for correction of the linear leakage current and for the subtraction of the residual capacitance [24]. The current recordings were performed on 35 mm diameter acrylic Petri dishes using inverted microscope (Axiovert 20, Carl Zeiss, Germany or Nikon TMF-100, Nikon, Japan). To record the TTXr current, after establishing the whole cell configuration and obtaining the total Na⁺ current, 100 μl of TTX-containing external solution was added to the bath solution to give a final TTX concentration of 300 nM. Data were acquired 20 s after TTX was added.

Data analyses

The Na⁺ current was recorded from neurons with capacitance ≤45 pF (diameters between 15 and 30 μm) [11, 29, 30]. Current voltage (I-V) relations were fitted with the equation

\[
I(V_m) = \frac{G_{max} \cdot (V_m - V_r)}{1 + e^{(V_m - V_{1/2})/k}}
\]

(1)

where \(I(V_m)\) is the current for a given membrane potential \(V_m\), \(V_r\) is the reversal potential, \(G_{max}\) is the maximum conductance, \(V_{1/2}\) is the half activation potential and \(k\) is the slope factor. The normalized conductance was obtained by the \(G/G_{max}\) ratio. Steady state inactivation curves were fitted with the equation

\[
h_{in} = \frac{1}{1 + e^{(V_h - V_{1/2})/k_h}}
\]

(2)

where \(V_h\) is the half inactivation potential and \(k_h\) is the slope of the steady state inactivation curve. The window current probability graph was obtained by the product between the equations for the steady state

| Table 1 | Comparison of glycemia levels (mg/dl of blood) between Control and Diabetic rats |
|---------|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|
|         | n | day 0 | day 15 | day 30 | day 45 | day 60 |
| Control | 24 | 95.4 ± 4.2 | 117.9 ± 1.7 |
| Diabetic | 16 | 127.5 ± 2.0 | 135.1 ± 4.5* |
| p value | 0.6687 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |

*Significant by Two Way ANOVA test, followed by Bonferroni (control vs diabetic)

| Table 2 | Comparison of mechanical thresholds (g) between Control and Diabetic rats |
|---------|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|
|         | day 0 | day 15 | day 30 | day 45 | day 60 |
| Control | 145.4 ± 3.3 | 179.3 ± 2.5 | 200.2 ± 4.3 | 210.1 ± 3.8 | 212.1 ± 5.9 |
| Diabetic | 135.1 ± 4.5* | 135.1 ± 4.5* | 135.7 ± 7.2* | 116.1 ± 5.8* | 116.1 ± 5.8* |
| p value | 0.5555 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |

*Significant by Two Way ANOVA test, followed by Bonferroni (control vs diabetic)
activation and the steady state inactivation curve \[31\], as described in Eq. 3.

\[
p = \frac{1}{1 + e^{(V_{1/2} - V_m)/k_1}} \cdot \frac{1}{1 + e^{(V_m - V_h)/k_2}}
\]

TTXs Na\(^+\) currents were isolated by digital subtraction between total Na\(^+\) current and TTXr Na\(^+\) current, the latter obtained by the use of TTX.

### Table 3
Comparison of TNF-\(\alpha\) serum concentration (pg/ml) between Control and Diabetic rats

|                | Day 0       | Day 60       |
|----------------|-------------|--------------|
| Control        | 343.0 ± 30.3 n = 3 | 340.3 ± 15.9 n = 7 |
| Diabetic       | 314.2 ± 18.2 n = 3 | 624.9 ± 97.8* n = 7 |
| p value        | 0.9031      | 0.0109       |

*Significant by One Way ANOVA test, followed by Bonferroni (control vs diabetic)

---

**Fig. 2** Effects of TNF-\(\alpha\) exposure on sodium current amplitude in DRG neurons

Representative trace of the total sodium current recorded from cells with and without exposure to TNF-\(\alpha\) (a), along with their normalized current density-voltage relations (b). c Peak current density values for the total sodium current with and without exposure to TNF-\(\alpha\). d, e, f same as in panels a-c but for the TTXs sodium current component. g, h, i same as in panels a-c but for the TTXr sodium current component. For panels c, f, and i, peak currents were measured at \(-5\) mV. * Total sodium current vs total sodium current after exposure to TNF-\(\alpha\), # TTXs sodium current vs TTXs sodium current after exposure to TNF, § TTXr sodium current vs TTXr sodium current after TNF exposure - \(p < 0.05\); One Way ANOVA test followed by Bonferroni. For panels b, e, and h, * Total sodium current vs total sodium current after exposure to TNF-\(\alpha\), # TTXs sodium current vs TTXs sodium current after exposure to TNF, § TTXr sodium current vs TTXr sodium current after TNF exposure - \(p < 0.05\); Two Way ANOVA test followed by Bonferroni.
Table 4 Comparison of the peak current density values (pA/pF) at a test potential of −5 mV between the INa Total, INa TTXs and INa TTXr with and without TNF-α

|                | INa Total | INa TTXs | INa TTXr |
|----------------|-----------|----------|----------|
| Control        | −134.7 ± 30.3 n = 8 | −89.7 ± 21.9 n = 5 | −58.2 ± 8.4 n = 8 |
| + TNF          | −227.9 ± 29.2* n = 14 | −177.0 ± 29.8* n = 11 | −95.9 ± 14.7* n = 12 |
| p value        | < 0.001   | 0.0027   | 0.0044   |

*Significant by One Way ANOVA test, followed by Bonferroni (control vs TNF)
Table 5 Comparison of the slope factor (k) values (mV) for steady state activation and steady state inactivation curves with and without TNF-α

|                      | steady state activation k factor | steady state inactivation k factor |
|----------------------|---------------------------------|-----------------------------------|
|                      | $h_{\text{Na}}$, Total          | $h_{\text{Na}}$, TTXs | $h_{\text{Na}}$, TTXr | $h_{\text{Na}}$, Total          | $h_{\text{Na}}$, TTXs | $h_{\text{Na}}$, TTXr |
| Control              | 7.2 ± 0.4 * n = 8               | 6.3 ± 0.5 n = 6               | 6.8 ± 0.5 n = 8               | -5.1 ± 0.2 n = 7               | -4.8 ± 0.2 n = 6               | -5.9 ± 0.1 n = 6               |
| + TNF                | 5.3 ± 0.2 * n = 14              | 4.8 ± 0.3 * n = 11             | 5.3 ± 0.8 n = 15             | 5.0 ± 0.3 n = 6               | -4.7 ± 0.4 n = 4               | -5.2 ± 0.5 n = 4               |
| p value              | < 0.001                         | 0.0012                         | 0.5598                        | 0.3861                         | 0.7267                         | 0.2197                         |

*Significant by One Way ANOVA test, followed by Bonferroni (control vs TNF)

Statistics

One- and two-way analysis of variance followed by Bonferroni tests was used for multiple comparisons as stated in the figure legends. Statistical significance was set at 0.05.

Results

Diabetic rats develop hyperalgesia and increasing in TNF-α serum concentration

Induction of diabetes by intraperitoneal (i.p.) STZ injection resulted in sustained hyperglycemia of diabetic rats for at least 60 days (Fig. 1a and Table 1). Concomitantly, the mechanical withdrawal thresholds of diabetic rats progressively decreased over the course of 60 days, whereas those of the control group showed a progressive increase over this time period, altogether indicating behavioral sensitization of the diabetic group (Fig. 1b and Table 2). We also assessed the TNF-α serum concentration of STZ treated and control rats. On day 60, the diabetic rats showed an elevation in TNF-α serum concentration level (Control, 340.3 ± 16.0 pg/ml vs Diabetic, 624.9 ± 97.8 pg/ml, day 60, Fig. 1c and Table 3).

TNF-α induces modulation of DRG neurons Na⁺ channels

As shown by Tamura et al. [16], adrenal chromaffin cells achieved maximum Nav1.7 protein expression after 6 hour exposure to 100 ng/ml TNF-α. Based on the findings of Fig. 1c and Table 3, the physiologically relevant TNF-α concentration (700 pg/ml) was added to the medium of dissociated DRG neurons for 6 hours. After 6 h of TNF-α exposure, the total Na⁺ current, as well as its TTXs and TTXr currents components were determined (Fig. 2). TNF-α induced an increase in the total Na⁺ current density in DRG neurons, as well as that of both the TTXs and TTXr components (Fig. 2c, f, j, and Table 4). In addition, total Na⁺ and TTXs currents appeared to activate at more negative voltages after TNF-α exposure, as evident from a leftward shift in the IV relation (Fig. 2b, e, h) and corresponding steady state activation curves (Fig. 3a, c, e, and Table 5), leading to a significantly more hyperpolarized half-activation voltage (Fig. b, d, f, and Table 6).

An analysis of steady state inactivation properties showed that the TTXs and TTXr currents respond differentially to TNF-α exposure. There was a leftward shift in the steady state inactivation curves for the total Na⁺ and TTXs currents, leading to a more hyperpolarized half-inactivation potential (Fig. 3a, c, e and Fig. 3b, d, f) that was not observed with TTXr currents. A calculation of the product of the activation and steady-state inactivation relationships reveals the impact of the TNF-α induced shifts on sodium window current (Fig. 4). TNF-α treatment slightly reduced total Na⁺ window current probability (Fig. 4a). Analyzing TTXs (Fig. 4b) and TTXr (Fig. 4c) components revealed that TNF-α treatment promoted both an increase in the peak and a slight leftward shift of the TTXs window current probability, whereas a reduction in TTXr window current probability is observed.

Altogether, these data indicate that a concentration of TNF-α equivalent to that seen in diabetic produces a gain of function predominantly in TTXs sodium currents of DRG neurons.

CRMP2 SUMOylation is not involved in TNF-α mediated increases in NaV1.7 membrane expression

Previous work has shown that CRMP2, in its SUMOylated form, is a potent regulator of Na⁺ channel membrane localization in the primary afferent pain pathway [21–24].
To determine whether TNF-α acts through this pathway, the total Na⁺ current was recorded from dissociated DRG neurons infected with AAV5 constructs encoding a CRMP2 SUMO-incompetent mutant protein, CRMP2-K374A-GFP. Control cells were infected with wild type CRMP2-GFP-AAV5 (Fig. 5). After being kept in culture for 2 weeks, the infected DRG neurons exhibited strong expression of the various CRMP2-GFP constructs (Fig. 5a–d) and robust Nav currents (Fig. 6a). DRG neurons infected with CRMP2-WT exhibited total Na⁺ current density (−89.4 ± 9.3 pA/pF) similar to that obtained in non-infected (control) DRG neurons (−94 ± 19.6 pA/pF, Fig. 6b, g, and Table 7). DRG neurons expressing CRMP2-K374A showed reduced total Na⁺ current density (−49.2 ± 5.3 pA/pF) when compared to both the control cells and CRMP2-WT cells (Fig. 6c, d, g and Table 7). After exposure to TNF-α, CRMP2-WT expressing cells showed a 40% increase in total Na⁺ current density (−137.6 ± 19 pA/pF) (Fig. 6f, g and Table 7). TNF-α treatment increased total Na⁺ current density in CRMP2-K374A expressing cells by about 50% (−76 ± 9.9 pA/pF) (Fig. 6e, g and Table 7). Hence, we conclude that interfering with CRMP2 SUMOylation does not preclude TNF-α mediated increases in Na⁺ current density.

**Discussion**

It has been shown that the elevation in basal glycemia is capable of promoting an increase in plasma TNF-α concentration, even in healthy non-diabetic individuals. In experiments performed in cell culture, hyperglycemic medium stimulates inflammatory signaling pathways that activate nuclear factor-κB (NF-κB) [32–34]. This may promote the transcription of TNF-α and its insertion into the endocrine/paracrine cycle signaling linked to TNF-α release, followed by new activation of NF-κB [35]. Li et al. [36] showed in cell cultures that hyperglycemic medium induces the expression of the metalloproteinase ADAM-17 which is consistent with the ensuing elevation in TNF-α serum concentration. There are also clinical findings that associate pro- and anti-inflammatory cytokine elevation in the blood serum with the induction and persistence of DNP in diabetic patients [37–39]. Ortman and Chattopadhyay [40] highlighted the importance of TNF-α as an additional pathogen in the development of diabetic neuropathy. These authors showed increased immuno-reactivity for TNF-α in histological sections of the DRG, dorsal horn of the spinal cord, sciatic nerve and paw skin of rats that developed hyperalgesia [41]. Several studies have correlated the elevation in plasma TNF-α concentration with alteration of the expression and/or function of voltage-dependent Na⁺ channels, critical elements in the establishment of neuronal excitability. In turn, this may be reflected, at least in part, in the reduction of the threshold for activation of the peripheral nerves, thus promoting the establishment of chronic neuropathic pain [42–46]. Thus, our data are in accordance with previous findings, since diabetic rats, with sustained hyperglycemia, exhibited both hyperalgesia and elevated TNF-α serum concentration levels.

Hyperalgesia to mechanical stimuli has been extensively reported in STZ-induced diabetic rats [47–50], and the data represented in Fig. 1 are in agreement with the literature. Like others [51–56], we observed an age-dependent increase in mechanical thresholds in control rats, whereas STZ injected rats showed a
slight decrease, overall consistent with the development of diabetic neuropathic pain. In diabetic rats with hyperalgesia, DRG neurons are known to exhibit increased action potential frequency in response to sustained suprathreshold mechanical stimulation [47, 57, 58] and increased spontaneous activity [59]. Both effects are thought to contribute to the development of pain [43] and are related to the activity of voltage-activated Na⁺ channels. Among these Na⁺ channels, the Nav1.7 isoform has been associated with a crucial role in the development of the DNP. Nav1.7 channels are robustly expressed in the cell bodies of virtually all neurons that act as nociceptive fibers Aδ and C [19, 60]. They are also present in both peripheral and central termini, with expression in the intraepidermal nerve fibers within the skin and dorsal root horn surface lamina, the region of greatest synaptic connectivity between primary and secondary nociceptive neurons [25]. Nav1.7 expression is increased in diabetic rats [11, 20, 61] and this effect has been linked to TNF-α expression in the DRG of these animals [61]. Based on this and in the work of Tamura et al. [16], we investigated how exposure of dissociated DRG neurons to relevant TNF-α concentrations may affect their Na⁺ currents.

Our results showed that TNF-α induces an increase of both TTXs and TTXr current density, which contributes to the overall increase in total Na⁺ current. Ding and colleagues reported a TNF-α mediated increase in Nav1.6 expression in rat DRG neurons [62], whereas Chen et al. [63] observed no change in the expression of the Na⁺ channel isoforms Nav1.1, 1.2, 1.3 or 1.6 in response to 8 h exposure to a TNF-α concentration of 1000 pg/ml. On the other hand, Nav1.7 was shown to increase its expression after only 6 h exposure to the same concentration of TNF-α [16]. Although other groups reported differences in total, TTXs or TTXr currents after a shorter duration of TNF-α exposure, this can be explained by the notion that

**Fig. 5** Confocal microscopy images taken from dissociated DRG neurons 2 weeks after viral infection. (a) Examples of DRG neurons expressing the CRMP2-WT tagged with GFP. b DRG neurons expressing the CRMP2-K374A with a GFP tag. c and d. Images of axons arising from DRG neuron cells bodies expressing CRMP2-WT-GFP and CRMP2-K374A-GFP, respectively.
Fig. 6 (See legend on next page.)
these authors used much higher TNF-α concentrations [28, 64, 65]. It is important to note that Na\textsubscript{1.7} is the main Na\textsuperscript{+} channel isoform expressed in A\textsubscript{6} and C fibers [66, 67], and hence it is thus possible that our observed changes in the TTXx Na\textsuperscript{+} current occurred are due to an increase in Na\textsubscript{1.7} expression. Further experimentation will be needed to attribute the expression of specific Nav isoforms confirm to our whole cell recordings.

We also observed a functional effect of TNF-α on the activation gating of the TTXx current component, an effect not seen with the TTXr Na\textsuperscript{+} current. A possible mechanism by which TNF-α alters the gating of TTXx channels may be through the ERK1 and ERK2 kinase phosphorylation and perhaps via p38 MAPK, both of which are activated by TNF receptors [21, 23, 68]. The latter mechanism has been reported to augment Na\textsubscript{1.8} single channel conductance [28, 59, 63], which would match the increased current density of the TTXx current. Increases in Nav1.8 and Nav1.9 expression in transgenic mice with elevated TNF-α levels have also been reported [31]. Indeed, we note that the TTXx Na\textsuperscript{+} current observed in our experiments may be carried by Nav1.8 channels, since the pipette solution does not contain CsF (or even F\textsuperscript{−}), necessary for the recording of the Na\textsuperscript{+} current conducted by the Na\textsubscript{1.9} isoform [69]. As noted above, a detailed dissection at the molecular level will be needed to validate such a possibility.

The mechanism by which TNF-α induces the increase in Na\textsubscript{1.7} channel expression has not yet been clarified. Recently, Dustrude et al. [70] demonstrated that Na\textsubscript{1.7} expression in the cell membrane can be modulated by the cytoplasmic protein CRMP2. This protein is highly expressed in neurons and oligodendrocytes of the central nervous system [47]. During central nervous system development, this protein also performs regulatory and structural functions related to cytoskeletal dynamics, vesicle traffic and synaptic activity, while its functions in the adult brain are still being elucidated. In addition, CRMP2 has been correlated with various neuropathological or psychiatric conditions, including Alzheimer’s disease and schizophrenia [71]. CRMP2 can be phosphorylated at several sites, SUMOylated, undergo addition of a β-N-acetyl-D-glucosamine group and be oxidized [72]. Among these, SUMOylation is a covalently reversible binding process between small ubiquitin-like modifying proteins (SUMO1, 2 or 3) and the substrate. According to the work of Dustrude et al. [70], inhibition of CRMP2 SUMOylation in DRG neurons reduces Nav1.7 channels trafficking from the nucleus to the cellular membrane surface. Moreover, depletion of

---

Table 7 Comparison of peak current density (pA/pF), at a test potential of −5 mV, recorded from Control cells and cells expressing various CRMP2 constructs with and without exposure to TNF-α

| Control | CRMP2 WT | CRMP2-K374A | CRMP2 WT + TNF-α | CRMP2-K374A + TNF-α | p value |
|---------|----------|-------------|------------------|---------------------|---------|
| −93.6 ± 19.6 n = 15 | −89.4 ± 9.2 n = 17 | – | – | – | 0.6722 |
| −93.6 ± 19.6 n = 16 | – | −492 ± 52* n = 19 | – | – | <0.0001 |
| −93.6 ± 19.6 n = 17 | – | – | −137.6 ± 18.9* n = 15 | – | <0.0001 |
| −93.6 ± 19.6 n = 18 | −89.4 ± 9.2 n = 17 | −492 ± 52* n = 19 | – | −760 ± 9.8 n = 11 | 0.1420 |
| −89.4 ± 9.2 n = 17 | −492 ± 52* n = 19 | – | −637 ± 18.9* n = 15 | – | <0.0001 |
| −89.4 ± 9.2 n = 17 | – | −637 ± 18.9* n = 15 | – | −760 ± 9.8 n = 11 | 0.2566 |
| −89.4 ± 9.2 n = 17 | – | −637 ± 18.9* n = 15 | – | −760 ± 9.8 n = 11 | 0.0245 |
| −89.4 ± 9.2 n = 17 | – | −637 ± 18.9* n = 15 | – | −760 ± 9.8 n = 11 | <0.0001 |

*, p < 0.05; One Way ANOVA test followed by Bonferroni

(−) indicates that the respective group is not part of the comparison on that row.
CRMP2 leads to a reduction in the Na⁺ current density via Naᵥ1.7. In our hands, DRG neurons expressing the CRMP2-K374A protein showed reduced total Na⁺ current density when compared to both the control group neurons and neurons expressing the CRMP2-WT protein, in agreement with the work of Dustrude et al. [70]. Nonetheless, TNF-α potentiates TTXs currents in the presence of either WT or mutant CRMP2, indicating that TNF-α effects occur independently of CRMP2. Further work will be required to define the precise cell signaling pathways that underlie the action of TNF-α on Na⁺ channels in sensory afferents.

In conclusion, TNF-α, at a serum concentration similar to that measured in STZ-induced diabetic rats, is capable of modulating Na⁺ current in dissociated DRG neurons after 6 h exposure. Although this effect is independent of SUMOylation of CRMP2, the TNF-α-mediated enhancement of Na⁺ channel expression could potentially be exploited for therapeutic intervention into diabetic pain.

**Abbreviations**

CRMP2: collapsin response mediator protein 2; DNP: diabetic neuropathy pain; DRG: Dorsal root ganglia; Nav: voltage dependent sodium channel; PDN: peripheral diabetic neuropathy; STZ: Streptozotocin; TNF-α: tumor necrosis factor alpha; TTX: tetrodotoxin; TTXr: tetrodotoxin resistant; TTXs: tetrodotoxin sensitive

**Acknowledgements**

Not applicable.

**Author contributions**

FM performed experiments, analyzed the data and wrote the first draft of the manuscript. RA, EF, DM, LC, F-XZ, IS, VL, RCMF, TR and AM performed experiments and/or provided reagents. JSC, RK and GWZ supervised the study and edited the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by the Brazilian funding agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). JSC is CNPq research fellow (Grant #312474/2017–2), and by a grant to GWZ from the Canadian Institutes of Health Research (CIHR). GWZ holds a Canada Research Chair.

**Availability of data and materials**

The data used in our study are available from the authors on reasonable request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Brazil. 2Department of Physiology and Pharmacology, Hotchkiss Brain Institute and Alberta Children’s Hospital research Institute, University of Calgary, Calgary, Canada. 3Department of Pharmacology, University of Arizona, Tucson, AZ, USA.

**Received:** 29 October 2019 **Accepted:** 17 December 2019

**Published online:** 30 December 2019

**References**

1. World Health Organization. Diabetes. [Internet]. Available from: https://www.who.int/health-topics/diabetes. [Cited 29 Oct 2019].
2. World Health Organization. Geneva (CH): WHO Press; 2014. 302. Report No.: 2.
3. World Health Organization. Diabetes. [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes. 2018 [Cited 29 Oct 2019].
4. Matthews CD, Lonnar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
5. Callaghan BC, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffett H, Karter AJ. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care. 2011;34(3):e35–40.
6. Boulton AJ, Vinik AI, Arezzo JC, Brill V, Feldman EL, Freeman R, Malik RA, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2002;25(4):956–62.
7. Pop-Busui R, Boulton AJ, Feldman EL, Brill V, Freeman R, Malik RA, Sosenko JM, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–54.
8. Boulton AJ, Kironer RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351(11):54–55.
9. Tesfaye S, Boulton AJ, Dickerson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36(9):2456–65.
10. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol. 2002;52(6):785–92.
11. Hong S, Morrow TJ, Paulson PE, Iomom LL, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem. 2004;279(28):29341–50.
12. Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998;18(23):9607–19.
13. Cummins TR, Agileo F, Renganathan M, Herzog RI, Dib-Hajj SD, Waxman SG. Nav.1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J Neurosci. 2001;21(16): 5952–61.
14. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol. 2003;551(Pt 3): 741–50.
15. Galloway C, Chattopadhyay M. RETRACTED: increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in type 2 diabetes. Cytokine. 2013;63(1):1–5.
16. Tamura R, Nemoto T, Maruta T, Onizuka S, Yasugata T, Wada A, Murakami M, et al. Up-regulation of Nav1.7 sodium channels expression by tumor necrosis factor-alpha in cultured bovine adrenal chromaffin cells and rat dorsal ganglion neurons. Anesth Analg. 2014;118(3):318–24.
17. Zhang JL, Yang JP, Zhang JR, Li RQ, Wang J, Jan JJ, Zhuang Q. Gabapentin reduces allosthyria and hyperalgesia in painful diabetic rat by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res. 2013;1493:13–8.
18. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci. 2010;33:325–47.
19. Djouhri L, Newton R, Levinson SR, Berry CM, Carruthers B, Lawson SN. Sensory and electrophysiological properties of Guinea-pig sensory neurones expressing Nav1.7 (PN1) Nav-channel alpha subunit protein. J Physiol. 2003;546(Pt 2):565–76.
20. Chattopadhyay M, Mata M, Fink DJ. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (Nav1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci. 2008;28(26):6652–8.
21. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in sensory and nociceptive afferents from painful human neuromas. Ann Neurol. 2002;52(6):785–92.
22. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol. 2002;52(6):785–92.
23. Barbin G, Roisin MP, Zalc B. Tumor necrosis factor alpha activates the phosphorylation of ERK, SAPK/JNK, and P38 kinase in primary cultures of neurons. Neurochem Res. 2001;26(2):107–12.

24. Bezannia F, Armstrong CM. A low-cost signal averager and data-acquisition device. Am J Physiol. 1973;225(2):C21–5.

25. Black JA, Frézel N, Dib-Hajj SD, Waxman SG. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central pretectal branches and terminals in the dorsal horn. Mol Pain. 2012;8:82.

26. Khomula EV, Vlatchenko-Karpinski VY, Borisyuk AL, Dudzy DE, Belan PV, Voitenko NV. Significant functioning of Cav3.2-type calcium and TRPV1 channels under different types of STZ-diabetic neuropathy. Biochim Biophys Acta. 2013;1832(5):636–49.

27. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of insulin on skeletal muscle cells. Diabetes. 1999;48(4):855–64.

28. Jin X, Gereau RW 4th. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-α. J Neurosci. 2006;26(1):1246–55.

29. Harnada K, Natsuura H, Sanada M, Toyoda T, Omathu-Kambe M, Kashiwagi A, Yasuda H. Properties of the Na(+)/K+ pump current in small neurons from adult rat dorsal root ganglia. Br J Pharmacol. 2003;138(8):1517–27.

30. Leo M, Argalski S, Schäfers M, Hagenacker T. Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor-1 and Receptor-2 in small DRG neurons of rats. Mediat Inflamm. 2015;2015:124942.

31. Fischer BD, Ho C, Kuzin I, Bottaro A, O’Leary ME. Chronic exposure to tumor necrosis factor α HSV-mediated gene transfer of TNF-α in rat dorsal root ganglia and spinal cord in experimental models of neuropathic rats. Mol Pain. 2014;10:49.

32. Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, Zhang XF, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain. 2006;123(1–2):75–82.

33. Tanaka T, Minami M, Nakagawa S, Tato M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res. 2004;48(4):463–9.

34. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience. 1993;52(4):1049–55.

35. Courteix C, Lavarenne J, Eschalier A, RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur J Pharmacol. 1993;241(2–3):267–70.

36. Kamei J, Ogawa M, Kasya Y. Development of supersensitivity to substance P in the spinal cord of the streptozotocin-induced diabetic rats. Pharmacol Biochem Behav. 1990;33(2):473–5.

37. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia. 1987;30(6):653–8.

38. Fitzgerald M, Gibson S. The postnatal physiological and neurochemical development of peripheral sensory c fibres. Neuroscience. 1984;13(3):933–44.

39. Fitzgerald M. The post-natal development of cutaneous afferent fibre input and receptive field organization in the rat dorsal horn. J Physiol. 1985;364:1–18.

40. Joshi SK, Mikusa JP, Shieh CC, Neelands T, Zhang XF, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain. 2006;123(1–2):75–82.

41. Tanaka T, Minami M, Nakagawa S, Tato M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res. 2004;48(4):463–9.

42. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience. 1993;52(4):1049–55.

43. Courteix C, Lavarenne J, Eschalier A, RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur J Pharmacol. 1993;241(2–3):267–70.

44. Kamei J, Ogawa M, Kasya Y. Development of supersensitivity to substance P in the spinal cord of the streptozotocin-induced diabetic rats. Pharmacol Biochem Behav. 1990;33(2):473–5.

45. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia. 1987;30(6):653–8.

46. Fitzgerald M, Shaw A, MacIntosh N. Postnatal development of the cutaneous afferent fibre input and receptive field organization in the rat dorsal horn. J Physiol. 1985;364:1–18.

47. Fitzgerald M, Shaw A, MacIntosh N. Postnatal development of the cutaneous afferent fibre input and receptive field organization in the rat dorsal horn. J Physiol. 1985;364:1–18.
69. Coste B, Osorio N, Padilla F, Crest M, Delmas P. Gating and modulation of presumptive NaV1.9 channels in enteric and spinal sensory neurons. Mol Cell Neurosci. 2004;26(1):123–34.
70. Dustrude ET, Wilson SM, Ju W, Xiao Y, Khanna R. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem. 2013;288(34):24316–31.
71. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodegeneration indications. Mol Neurobiol. 2011;43(3):180–91.
72. Khanna R, Wilson SM, Brittain JM, Weimer J, Sultana R, Butterfield A, Hensley K. Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol. 2012;7(6):749–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.